Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy

Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers, yet not all patients respond. We report the evaluation of >300 patient samples across 22 tumor types from four KEYNOTE clinica...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Science (American Association for the Advancement of Science) Ročník 362; číslo 6411
Hlavní autoři:	Cristescu, Razvan, Mogg, Robin, Ayers, Mark, Albright, Andrew, Murphy, Erin, Yearley, Jennifer, Sher, Xinwei, Liu, Xiao Qiao, Lu, Hongchao, Nebozhyn, Michael, Zhang, Chunsheng, Lunceford, Jared K, Joe, Andrew, Cheng, Jonathan, Webber, Andrea L, Ibrahim, Nageatte, Plimack, Elizabeth R, Ott, Patrick A, Seiwert, Tanguy Y, Ribas, Antoni, McClanahan, Terrill K, Tomassini, Joanne E, Loboda, Andrey, Kaufman, David
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 12.10.2018
Témata:	Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Biomarkers, Tumor - genetics Cell Cycle Checkpoints Genetic Markers Humans Immunotherapy Inflammation - genetics Molecular Targeted Therapy - methods Mutation Neoplasms - genetics Neoplasms - therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors T-Lymphocytes - immunology Transcriptome Tumor Burden - genetics
ISSN:	1095-9203, 1095-9203
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!